Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-11-06
2007-11-06
Yu, Misook (Department: 1642)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S320100, C435S069600
Reexamination Certificate
active
10280716
ABSTRACT:
The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
REFERENCES:
patent: 5326859 (1994-07-01), Sugano et al.
patent: 5468609 (1995-11-01), Revel et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5554513 (1996-09-01), Revel et al.
patent: 5559012 (1996-09-01), Brailly et al.
patent: 5591827 (1997-01-01), Brakenhoff et al.
patent: 5618700 (1997-04-01), Novick et al.
patent: 5618920 (1997-04-01), Robinson et al.
patent: 5639455 (1997-06-01), Shimamura et al.
patent: 5723120 (1998-03-01), Brakenhoff et al.
patent: 5789552 (1998-08-01), Savino et al.
patent: 5807715 (1998-09-01), Morrison et al.
patent: 5849283 (1998-12-01), Ciliberto
patent: 5854398 (1998-12-01), Chang et al.
patent: 5856135 (1999-01-01), Tsuchiya et al.
patent: 5888510 (1999-03-01), Kishimoto et al.
patent: 5888511 (1999-03-01), Shurkovich et al.
patent: 5914106 (1999-06-01), Ciliberto
patent: 5942220 (1999-08-01), Warren et al.
patent: 5958400 (1999-09-01), Ruben et al.
patent: 5972902 (1999-10-01), Ciliberto
patent: 6010864 (2000-01-01), Hoeprich, Jr.
patent: 6086874 (2000-07-01), Yoshida et al.
patent: 6121423 (2000-09-01), Tsuchiya et al.
patent: 6261560 (2001-07-01), Tsujinaka et al.
patent: 800829 (1997-10-01), None
patent: WO9108774 (1991-06-01), None
patent: WO9409138 (1994-04-01), None
Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295, under the heading “Fv Structure and Diversity in Three Dimensions”.
Rudikoff et al, Proc. Natl. Acad. Sci. USA 1982 vol. 79: p. 1979.
Cruse and Lewis, Illustrated Dictionary of Imunology, 1995, p. 19.
Just P.J. Brakenhoff, Margaret Hart, Els R. De Groot, Franco Di Padova and Lucien A. Aarden, “Structure-Function Analysis of Human IL-6-Epitope Mapping of Neutralizing Monoclonal Antibodies with Amino-and Carboxyl-Terminal Detetion Mutants” The Journal of Immunology, vol. 145, 561-568 No. 2, Jul. 15, 1990, USA.
Just P.J. Brakenhoff, Els R. De Groot, Ron F. Evers, Hans Pannekoek & Lucien A. Aarden Molecular Cloning and Expression of Hybridoma Growth Factor in Escherichia Coli, The Journal of Immunology, vol. 139, 4116-4121, No. 12, Dec. 15, 1987 USA.
H.C.T. Van Zaanen, H. M. Lokhorst, L A. Aarden, H. J. A. M. Rensink, S. O. Warnaar, M. H. J. Van Oers, Blocking Interleukin-6 Activity with Chimeric Anti-IL6 Monoclonal A ntibodies in Multiple Myeloma: Effects on Soluble IL6 Receptor and Soluble gp130, Leukemia & Lymphoma vol. 31, 31 (5-6)pp. 551-558.
H.C.T. Van Zaane, R. P. Koopmans, L. A. Aarden, H. J. A.M. Rensink, J.M.L. Stouthard, S.O. Warnaar, H.M. Lokhorst and M.H.J. Van Oers Endogenous Interleukin 6 Production in Multiple Myeloma Patients Treated with Chimeric Monoclonal Anti-IL6 Antibodies Indicates the Existence of a Positive Feed-back Loop, J. Clin. Invest., The American Society for Clinical Investigation, Inc., vol. 98, No. 6, Sep. 1996, 1441-1448, The Netherlands.
H.C.T. Van Zaanen, H. M. Lokhorst, L. A. Aarden, H. J. A. M. Rensink, S. O. Warnaar, J. Van Der Leue, M. H. J. Van Oers, Chimaeric anti-Interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a Phase I dose—escalating study, British Journal of Haematology (102,783-790, 1998.
Jose Baselga and John Mendelsohn “Receptor Blockage with Monocional Antibodies as Anti-Cancer Therapy,” Pharmac Ther. vol. 64, pp. 127-154, 1994 Elsevier Science Ltd. Great Britain.
Matsuda, et al, Eur. Journal Immunol. 18:951-956 (1988).
Seidman, Jonathan, Peritt David, “A novel monoclonal antibody screening method using the Luminex-100™ microsphere system,” J. Immunol. Methods 267: 165-171, 2002.
Josebaselga and John Mendelsohn “Receptor Blockage with Monoclonal Antibodies as Anti-Cancer Therapy,” Pharmac Ther. vol. 64, pp. 127-154, 1994 Elsevier Science Ltd., Great Britain.
Orlandi et al, Cloning Immunoglobulin variable domains for expression by the polymerase chain reaction. Proc. Natl. Accad. Sci. USA, May 1989, vol. 86, pp. 3833-3837, especially p. 3835.
Brakenhoff et al, “Epitope Mapping of Neutralizing Monoclonal Antibodies with Amino- and Carboxyl-Terminal Detetion Mutuants,” Journal of Immunology, 1990, vol. 145, pp. 561-568, USA.
Sato, K. et al.: Humanization of an Anti-Human IL-Mouse Monoclonocal Antibody Glycosylated in its Heavy Chain Variable Region Human Antibodies and Hydridomas, vol. 7, No. 4, 1996, pp. 175-183 XP008041468.
Naka, T. et. al: “The Paradigm of IL-6: From Basic Science to Medicine” Arthritis Research, Current Science, London,, GB vol. 4, No. SuppL. 3, May 9, 2002, pp. S233-S242, XP009031052.
EP Supplementary Search Report dated Jul. 24, 2006 for EP Appl. No. 02784436.4.
R.V. Petrov, “Immunology,” Medicine Publishers, 56-58 (1987), Russian Article and Engliish translation.
Giles-Komar Jill
Knight David
Peritt David
Trikha Mohit
Centocor, Inc.
Dow Kenneth J.
Halvorson Mark
Yu Misook
LandOfFree
Anti-IL-6 antibodies, compositions, methods and uses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-IL-6 antibodies, compositions, methods and uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-IL-6 antibodies, compositions, methods and uses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3852026